Abstract:Cefixime is a broad-spectrum oral antibiotic used for treating a wide variety of bacterial infections. Study Objective: The objective of this study was to find out whether bioequivalence study of Cefixime 200 mg, Profim® capsule manufactured by PT Promedrahardjo Farmasi Industri in comparison with Cefixime 100 mg, Cefspan® capsule manufactured by PT Dankos Farma, For PT Kalbe Farma Tbk, under license by Astellas Pharma Inc., Osaka – Japan. Methods: The study was conducted using an open-label, randomized, single-dose, two-periods, two-treatments, crossover study under fasting conditions with 8 (eight) days washed-out period between each period. According to the random design, a single oral dose of the test drug or reference drug was administered to 30 healthy male subjects after overnight fasting. The number of subjects who finished the study was twenty-eight (28) healthy male subjects. Serial plasma samples were obtained over a 32 hours period. Plasma concentrations of the drug were determined by LC-MS/MS method. From the Cefixime concentration vs. time curves, the following pharmacokinetic parameters were obtained: AUC0-32h, AUC0-∞, and Cmax, while the statistical interval proposed was 80.00 - 125.00% for AUC0-32h and Cmax with 90% Confidence Interval (CI) with α = 5.00%. The estimation of Tmax and T1/2 in the bioequivalence study was based on a nonparametric statistical procedure on the original data using Wilcoxon Sign Test. Results: The main pharmacokinetic parameters of the test drug Profim® (BN: B051A21P-1)/ reference drug, Cefspan® (BN: KCEFB00038) ratio were as follows: AUC0-32h: 105.86 (95.41 - 117.44) with CV Intra Subjects was 22.72% and Cmax: 105.63 (95.33 - 117.03) with CV Intra Subjects was 22.43 %. Whilst TMAX of the test drug Profim® (BN: B051A21P-1)/ reference drug, Cefspan® (BN: KCEFB00038) were respectively 4.50 (3.50 – 6.00) h and 4.50 (3.00 – 6.00) h; mean T1/2 were respectively 4.18 ± 0.78 h and 4.14 ± 0.56 h; and mean Slope were respectively (-0.17) ± 0.03 h and (-0.17) ± 0.02 h. There is no adverse event that occurred during this study. Conclusion: The present study demonstrated that the evaluated test drug Profim® (BN: B051A21P-1) were bioequivalence in term of both rate and extent of absorption to the reference drug Cefspan® (BN: KCEFB00038).

Relative bioavailability of cefpodoxime proxetil tablets in healthy volunteers

Pharmacokinetics and relative bioavailability of domestic vs imported cefpodoxime proxetil tablets in human body

Study on bioequivalence of cilostazol table in healthy volunteers

Comparison of External Dissolution among Four Kinds of Cefpodoxime Proxetil Tablets

The bioavailability of cefpodoxime proxetil tablets relative to an oral solution

Pharmacokinetics and Bioequivalence Study of Cefixime Tablet in Healthy Volunteers

Bioequivalence Study of Domestic Made Cefpodoxime Proxetil Capsules in Healthy Volunteers

Pharmacokinetic and Bioequivalence Evaluation of Two Cefprozil Dispersible Tablets in Healthy Chinese Volunteers

Bioavailability of Cefuroxime Axetii Suspension in Healthy Volunteers

Clinical Pharmacokinetics of Cefprozil and Bioequivalence Between Its Tablet and Suspension

Bioequivalence of two tablet formulations of cefpodoxime proxetil in beagle dogs

Relative bioavailability and bioequivalence of clopidogrel hydrogen sulfate tablets in healthy volunteers

Bioequivalence of domestic and imported ceftibuten tablets in healthy volunteers

Bioequivalence of Levodopa Tablets in Healthy Volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Bioequivalence Study of Two Formulations of Cefixime

Bioequivalence of Clarithromycin Dispersed Tablet in Health Volunteers

Bioequivalence Study of High Performance Liquid Chromatography Towards Cefetamet Pivoxil

Pharmacokinetics and bioequivalence of roxithromycin capsules in healthy volunteers

Bioavailability of cefpodoxime proxetil with co-administered acetylcysteine

Bioequivalence of Azithromycin Tablets in Healthy Volunteers